ArticleUrology2026
Treatment-related Risk of Urologic Adverse Events in Cervical Cancer Survivors.
Article in Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the risk of urologic adverse events (UAE), including ureteral complications and urinary fistula, in women treated for cervical cancer to inform clinical decision-making and improve survivorship quality of life.
methodsUsing the Merative MarketScan database (2011-2021), patients with cervical cancer were identified. Exclusions included <1 year pre-diagnosis enrollment, prior radiotherapy, pre-existing UAE, or multiple gynecologic cancers. Patients were categorized by treatment: surgery alone, surgery + chemotherapy, radiation ± other therapies, no/local treatment, and chemotherapy or radiation alone (surrogate for metastatic disease). Healthy age-matched controls were used. Multivariate Cox models and Kaplan-Meier analyses estimated UAE risk over time. UAEs were stratified as low-, intermediate and high-grade events.
resultsAmong 96,522 patients (68,990 cases and 27,532 controls), higher rates of all UAE were observed in cervical survivors than controls (23.2% vs 17.9%, P < .001). The highest risks of UAE were observed in patients with presumed non-metastatic disease who received radiation (low-grade UAE: HR 3.7, P < .001; intermediate-grade: HR 9.6, P < .001; high-grade UAE: HR 13.7, P < .001, ureteral: HR 23.5, P < .001, and fistula: HR 63.3, P < .001).
conclusionCervical cancer treatment, particularly involving radiation, is associated with substantial risk high-grade UAE, ureteral and fistula complications. For young patients with localized and presumably curable disease, improved counseling, monitoring, and research to mitigate these highly morbid urologic complications is imminently warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.